Neurocrine Biosciences, Inc. (NBIX)
- Simply Wall St.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices...
- PR Newswire
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules for the long-term treatment of adults with chorea associated with Huntington's disease. Robust and sustained improvements in chorea associated with Huntington's disease were observed through Week 104 in patients, irrespective of concomitant antipsychotic therapy use. These results (Poster #1465) will be presented on September 30 during the
- PR Newswire
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday, September 26, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference.
